Evidence map›Paper›PMID 42440198›Full record

ArticleCell biology and toxicology2026

PIK3CB depletion restores immunosurveillance and enhances radioactive iodine response in hepatocellular carcinoma.

Yuanren Gao, A Rouhan, Wenbo Wang, Tengchuang Ma, Yali Cui

Abstract read
In one paragraph

Article in Cell biology and toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuanren GaoDepartment of Nuclear Medicine, Harbin Medical University Cancer Hospital, Harbin, 150081, Heilongjiang, People's Republic of China.
A RouhanDepartment of Nuclear Medicine, Harbin Medical University Cancer Hospital, Harbin, 150081, Heilongjiang, People's Republic of China.
Wenbo WangDepartment of Nuclear Medicine, Harbin Medical University Cancer Hospital, Harbin, 150081, Heilongjiang, People's Republic of China.
Tengchuang MaDepartment of Nuclear Medicine, Harbin Medical University Cancer Hospital, Harbin, 150081, Heilongjiang, People's Republic of China. matengchuang1988@126.com.
Yali CuiDepartment of Nuclear Medicine, Harbin Medical University Cancer Hospital, Harbin, 150081, Heilongjiang, People's Republic of China. 0012@hrbmu.edu.cn.

Funding

National Natural Science Foundation of China 8227071164
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) has a high incidence and mortality rate despite the existence of various treatments, including iodine-125 (

Indexed as

Carcinoma, HepatocellularClass Ib Phosphatidylinositol 3-KinaseImmunologic SurveillanceIodine RadioisotopesLiver NeoplasmsAnimalsB7-H1 AntigenCell Line, TumorGene Expression Regulation, NeoplasticHumansKiller Cells, NaturalMiceRepressor ProteinsTranscription FactorsTumor EscapeB7-H1 AntigenClass Ib Phosphatidylinositol 3-KinaseIodine-125Iodine RadioisotopesRepressor ProteinsTranscription Factors125IHepatocellular carcinomaImmune evasionPD-L1PIK3CB

Identifiers

PMID42440198
PMCPMC13645882

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.